Table 1.

List of compounds used and their antimicrobial activity²⁹.

ID	Sequence	R.ta	S.p.b	S.a.c	P.a.d
1	Lys-Lys-Leu-Lys-(2-Nal)Ala-Phe-(2-Nal-)Ala	17.19	8	16	32
2	(N1-Nal)Gly-(N-Phe)Gly-(N1-Nal)Gly-(N-Bu)Gly-Lys-Lys-Lys	17.43	8	16	32
3	(2-Nal)Ala-Phe-(2-Nal)Ala-Lys-Leu-Lys-Lys	15.84	16	32–64	> 64
4	(2-Nal)Ala-Phe-(2-Nal)Ala-Leu-Lys-Lys-Lys	16.47	16	32	> 64
5	(1-Nal)Ala-Phe-(1-Nal)Ala-Leu-Lys-Lys-Lys	15.98	16	32	> 64
6	Lys-Lys-Leu-Lys-(1-Nal)Ala-Phe-(1-Nal)Ala	16.96	8	32	8
7	Lys-Lys-Lys-Leu-(1-Nal)Ala-Phe(1-Nal)Ala	17.21	8	16	16
8	(1-Nal)Ala-Phe-(1-Nal)Ala-Lys-Leu-Lys-Lys	15.41	16	32–64	> 64
9	(1-Nal)Ala-Phe-(1-Nal)Ala-Leu-Lys-Lys-Lys	16.11	16	32	32
10	Lys-Lys-Leu-Lys-(1-Nal)Ala-Phe-(1-Nal)Ala	16.81	4–8	16	16–32
11	Lys-Lys-Lys-Leu-(1-Nal)Ala-Phe-(1-Nal)Ala	17.52	2	8	8
12	Lys-Lys-Lys-Leu-(2-Nal)Ala-Phe-(2-Nal)Ala	17.70	2–4	8–16	32
13	(2-Nal)Ala-Phe-(2-Nal)Ala-Lys-Leu-Lys-Lys	16.31	4–8	16	64
14	Lys-Lys-(N-Bu)Gly-Lys-(N1-Nal)Gly-(N-Phe)Gly-(N1-Nal)Gly	17.48	4	8–16	32
15	Lys-Lys-Lys-(N-Bu)Gly-(N1-Nal)Gly-(N-Phe)Gly-(N1-Nal)Gly	17.89	4	16	32
16	(1-Nal)Ala-Phe-(1-Nal)Ala-Lys-Leu-Lys-Lys	16.20	8–16	16–32	64
17	Lys-Lys-Lys-Leu-(2-Nal)Ala-Tyr-(2-Nal)Ala	16.62	16	> 64	> 64
18	Lys-Lys-Lys-Nle-(2-Nal)Ala-Phe-(2-Nal)Ala	17.46	2–4	32–64	8
19	Lys-Lys-Lys-Leu(1-Nal)Ala-Tyr-(1-Nal)Ala	17.36	n.t.e	> 64	> 64
20	Lys-Lys-Lys-Nle-(1-Nal)Ala-Phe-(1-Nal)Ala	16.55	16–32	> 64	16
21	Lys-Lys-Lys-Leu-(1-Nal)Ala-Tyr-(1-Nal)Ala	16.70	2–4	32–64	8
22	Lys-Lys-Lys-Nle-(2-Nal)Ala-Tyr-(2-Nal)Ala	16.67	2–4	64	64
23	N-Lys-N-Lys-N-Lys-Leu-(2-Nal)Ala-Phe-(2-Nal)Ala	16.98	2–4	32	32
24	Lys-Lys-Lys-Leu-(2-Nal)Ala-Tyr-(2-Nal)Ala	17.67	4–8	16–32	32

d-residues denoted in bold.

^aRetention time (min).

^bMIC (µg/mL) against Staphylococcus pseudintermedius.

^cMIC (µg/mL) against Staphylococcus aureus.

^dMIC (µg/mL) against Pseudomonas aeruginosa.

^eNot tested.